Diamond-Blackfan anemia (DBA; OMIM 205900) is a rare congenital erythroid aplasia that usually presents in infancy [1] . The anemia is discovered early in life, usually within the first 2 years; diagnosis after 4 years of age is very unlikely. Physical anomalies are present in up to 50 % of patients with a wide range of severity. Patients have a modest increased risk of developing leukemia and other malignancies. DBA moved into the scientific limelight after the unexpected identification of the first DBA gene, ribosomal protein S19 (RPS19) [2] . The finding of mutations affecting other ribosomal protein genes establishes DBA as a disorder of ribosomal biogenesis and/or function. Here, we report the first Chinese DBA patient with a novel mutation in RPS19.
A 12-year-old boy was referred to our hospital with anemia with no other significant cytopenias. His parents and an 8-year-old sister were healthy. Palor was first found at 1 month after birth and the patient had received two blood transfusions within the first 2 months of life. The diagnosis of DBA was established by 3 months by bone marrow aspiration which showed normocellular marrow with myeloid-to-erythroid ratio of 60:1, grossly reduced red cell precursors and normal other cell lines. The patient was then treated with glucocorticoid. He had a good response to steroids until 7 years old; during the treatment period his hemoglobin levels maintained 11-12 g/dL. Since then, he failed to respond to steroids. Chronic transfusion therapy with iron chelation was reinstituted. He received transfusion every 2-3 weeks to maintain a hemoglobin level between 8 and 9 g/dL.
At this referral, the patient's height was 151 cm and weight 51.5 kg. His mental status was normal. He had no congenital malformations and no other cytopenias. A repeat marrow biopsy was not done. Genetic studies were performed for screening the mutations in the eight genes known to be associated with DBA, RPS19, RPS24, RPS17, RPL5, RPL11, RPL35A, RPS10, and RPS26. A missense point mutation (c.188A [ C; p.His63Pro) was identified in the exon 4 of RPS19 gene in the patient (Fig. 1) . However, this mutation was not found in either of the parents (Fig. 1) , thus suggesting a de novo origin. The c.188A [ C variant of RPS19 has not been reported previously following literature search in PubMed and mutation search in web-accessible Leiden Open Variation Database (LOVD). To confirm that c.188A [ C in the RPS19 gene is not a polymorphism, a total of 100 unrelated healthy individuals were also screened for the same mutation. This mutation was not identified in 200 control chromosomes.
DBA has been associated with heterozygous mutations in ten ribosomal protein (RP) genes; six small subunit RP genes RPS7, RPS10, RPS17, RPS19, RPS24, and RPS26; and four large subunit RP genes RPL5, RPL11, RPL35A, and RPL26 [3, 4] . Mutations in these genes have been reported in *55 % of DBA patients. The RPS19 protein plays an important role in 18S rRNA maturation in both yeast and human cells [5, 6] . All the RPS19 mutations were found in heterozygosity with the wild-type sequence; this is consistent with the dominant inheritance pattern and with the evidence that the RPS19 knockout is lethal prior to implantation in mice [7] . Mutations are heterogeneous and span the whole gene, and missense mutation is the most frequent subtype. According to its location on protein structure, the p.His63Pro belongs to class II mutations. These mutations, which are much more conserved, are located on the surface of RPS19 and hence may affect its interaction with its environment and impair its function without altering its folding [8] .
More than half a century after the original report of their efficacy, steroids remain the mainstay of therapy for patients with DBA. However, the patients may becomes unresponsive without any known reasons even they have being highly steroid responsive for a long time, as evidenced by our patient. The identification of pathogenic mutations in RPS19 provided a definite diagnosis of DBA in this patient who was waiting for a suitable donor for hemopoietic stem cell transplantation.
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